Mr. Renaud joined Bain Capital Life Sciences in 2022. From 2014 to 2021, he was Chief Executive Officer of Translate Bio (Nasdaq: TBIO) which was acquired by Sanofi in 2021. Prior to that he was President and Chief Executive Officer of Idenix Pharmaceuticals (Nasdaq: IDIX) which was acquired by Merck in 2014. Prior to his career in the biotech industry, Ron was a biotechnology research analyst at JP Morgan and Bear Stearns. Earlier in his career, Ron held various roles at Amgen (Nasdaq: AMGN) as well as at the Dana-Farber Cancer Institute.

Mr. Renaud received an MBA from the University of Southern California Marshall School of Business and a BA from Saint Anselm College.

Mr. Field joined Bain Capital Life Sciences in 2020 as an Associate. Prior to joining Bain Capital, Mr. Field was a management consultant at Bain & Company in New York. At Bain & Co, Mr. Field advised healthcare and private equity clients across a range of different strategic and operational problems. Mr. Field also worked in Commercial Strategy and Investor Relations at a biotech company prior to joining Bain Capital.

Mr. Field graduated magna cum laude from Dartmouth College, where he earned a B.A. in Biology and Economics.

Joel came to Jnana from Achillion Pharmaceuticals, where he served as their chief scientific officer. Most of Joel’s career was spent as a medicinal chemist in pharma, where he capped a 28-year career at Bristol-Myers Squibb by spending the last five years as vice president and head of discovery chemistry, working across all therapeutic areas. In that role, Joel worked with teams responsible for advancing more than 40 compounds into clinical development, including Sprycel (dasatinib), which he co-invented. While at BMS, Joel and his colleagues made notable advances in the area of kinase inhibitor drug discovery, particularly in immunology and oncology. He is a co-author on over 130 peer reviewed publications and is a co-inventor on 40 issued U.S. patents. Prior to moving to BMS, he spent five years at Hoffmann La-Roche as a research scientist. Joel received his doctorate in organic chemistry from Columbia University and his bachelor’s in chemistry from the University of Pennsylvania.